Malaria, a parasitic disease caused by protozoa belonging to the genus Plasmodium,
continues to represent a formidable public health challenge. Despite being a preventable …

Background We evaluated existing data on the prophylactic efficacy of atovaquone-
proguanil (AP) in order to determine whether prophylaxis in travellers can be discontinued …

We conducted a prospective cohort study to assess adherence to malaria
chemoprophylaxis, reasons for nonadherence, and use of other personal protective …

Background Atovaquone-proguanil is considered causal prophylaxis (inhibition of liver-
stage schizonts) for Plasmodium falciparum; however, its causal prophylactic efficacy for …

Background International travel, particularly to developing countries, is becoming
increasingly common among the Israeli population, including an increase in the number of …

Background: Current guidelines recommend daily dosing of atovaquone–proguanil (AP),
beginning a day before travel to endemic areas and continuing for 7 days after departure …

According to current guidelines, atovaquone-proguanil (AP) malaria chemoprophylaxis
should be taken once daily starting one day before travel and continued for seven days post …

Malaria chemoprophylaxis is probably the most complex area of pretravel advice. The travel
medicine advisor must have in-depth knowledge of all available chemoprophylactic drugs …

The combination of Atovaquone and Proguanil (Malarone™) has been widely used for
treatment and prevention of Plasmodium falciparum malaria. Transient elevation of liver …

International travels for tourism and business purposes continue to increase annually, while
the global terrorism and the risk of lethal viral infections are currently real concerns. It is …